People: AMAG Pharmaceuticals Inc (AMAG.O)

AMAG.O on Nasdaq

36.00USD
21 Nov 2014
Price Change (% chg)

$0.41 (+1.15%)
Prev Close
$35.59
Open
$36.09
Day's High
$36.16
Day's Low
$34.88
Volume
390,886
Avg. Vol
522,004
52-wk High
$36.40
52-wk Low
$16.49

Search Stocks

Summary

Name Age Since Current Position

Gino Santini

57 2014 Chairman of the Board

William Heiden

54 2012 President, Chief Executive Officer, Director

Frank Thomas

44 2012 Chief Operating Officer, Executive Vice President

Scott Holmes

39 2014 Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer

Scott Townsend

47 2012 Senior Vice President - Legal Affairs, General Counsel, Secretary

Edward Jordan

46 2014 Senior Vice President - Sales and Marketing

Steven Caffe

54 2013 Senior Vice President, Chief Development and Regulatory Officer

Melissa Klug

2014 Senior Vice President - Business Development and Strategy

Robert Blood

2014 Chief Compliance Officer, Vice President - Legal Affairs

Judith Johnson

Vice President - Pharmacovigilance & Pharmacoepidemiology

John Fallon

66 2014 Director

Lesley Cooper

53 2009 Independent Director

Barbara Deptula

59 2013 Independent Director

Robert Perez

48 2009 Independent Director

Davey Scoon

67 2006 Independent Director

James Sulat

63 2014 Independent Director

Katie Payne

2013 Executive Director, Investor Relations & Corporate Communications

Biographies

Name Description

Gino Santini

Mr. Gino Santini is Chairman of the Board of AMAG Pharmaceuticals, Inc. From 1983 to 2010, Mr. Santini held a variety of commercial and operational roles at Eli Lilly and Company, or Eli Lilly, a public pharmaceutical company, serving most recently from April 2007 to December 2010 as Senior Vice President, Corporate Strategy and Business Development and as a member of the company's Executive Committee where he led corporate strategy and long-range planning, mergers and acquisitions, new product licensing and the expansion of Lilly Ventures in the United States and China. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004 and President of the women's health franchise from 1997 to 1999. Mr. Santini currently serves on the Board of Directors of Allena Pharmaceuticals, Inc., a pharmaceuticals company, where he has been a director since February 2012. He serves on the Board of Directors of Sorin S.p.A., a global medical device company, where he has been a director since April 2012, and on the Board of Directors of Finanziaria Saccarifera Italo Iberica S.p.A., a financial holding company, where he has been a director since January 2013. Mr. Santini also serves on the Board of Directors of Collegium Pharmaceuticals, Inc., a pharmaceutical company, where he has been a director since July 2012. Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council and of Noble of Indiana, a non-profit agency serving individuals with developmental disabilities. He also served on the Board of Directors for United Way and the Executive Committee and Board of Directors of the Indianapolis Chamber of Commerce. He holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester.

William Heiden

Mr. William K. Heiden is President, Chief Executive Officer, Director of AMAG Pharmaceuticals, Inc. Prior to joining the Company, he was the President and Chief Executive Officer of GTC Biotherapeutics, Inc., now rEVO Biologics, Inc., a pharmaceutical company, from June 2010 to May 2012 and continues to serve as its non-executive Chairman. Mr. Heiden was President and Chief Executive Officer and a member of the Board of Directors of Elixir Pharmaceuticals, Inc., or Elixir, a pharmaceutical company, from September 2004 until December 2008. Prior to joining Elixir, he served as President and Chief Operating Officer of Praecis Pharmaceuticals, Inc., a public biopharmaceutical company which was subsequently acquired by GlaxoSmithKline plc, from May 2002 to September 2004. From 1987 to 2002, Mr. Heiden held various positions of increasing responsibility at Schering-Plough Corporation, now Merck & Co., including managing a number of businesses in the United States, Europe and Canada. He serves on the Board of Directors of LFB Biotechnologies S.A.S., a private French biotechnology company. Mr. Heiden holds a B.A. from the University of Florida, an M.B.A. from Cornell University's Johnson Graduate School of Management, and a M.I.M. from the University of Louvain.

Frank Thomas

Mr. Frank E. Thomas is Chief Operating Officer, Executive Vice President of AMAG Pharmaceuticals Inc. He joined in August 2011 as Executive Vice President, Chief Financial Officer and Treasurer and currently serves as Executive Vice President and Chief Operating Officer. From November 2011 to May 2012, he also served as Interim President and Chief Executive Officer. Prior to joining, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., or Molecular Biometrics, a commercial stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., or Critical Therapeutics, a public biopharmaceutical company, from 2004 to 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas was the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc. Since 2007, he has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas holds a B.B.A. in Business Administration from the University of Michigan, Ann Arbor.

Scott Holmes

Mr. Scott A. Holmes is Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer of AMAG Pharmaceuticals, Inc. He joined in September 2011 as Vice President of Finance and Controller. He became Chief Accounting Officer in December 2011 and Principal Financial Officer and Treasurer in March 2012. Prior to joining Mr. Holmes served as Vice President of Finance and Treasurer of Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from June 2010 to September 2011. From August 2009 to May 2010, Mr. Holmes was Vice President of Finance and Administration at On-Q-ity Inc., an oncology diagnostics company. He served as a consultant with Altman & Company, a consulting firm, from January 2009 to August 2009. Prior to 2009, Mr. Holmes spent five years at Dynogen Pharmaceuticals, Inc., a privately held pharmaceutical company, as Vice President of Finance and Administration and Treasurer. He also served as the Controller at Keryx Biopharmaceuticals, Inc., a public biotechnology company from November 2001 to October 2003. Mr. Holmes holds a B.A. in History from Middlebury College and a dual M.S./M.B.A. degree from Northeastern University Graduate School of Business Administration.

Scott Townsend

Mr. Scott B. Townsend is Senior Vice President - Legal Affairs, General Counsel, Secretary of AMAG Pharmaceuticals Inc. In December 2009, Mr. Townsend founded External GC Law Group and until August 2012, provided legal advice to a variety of life science companies, including biopharmaceutical and medical device companies. From October 2008 to June 2009, he served as Executive Vice President of Legal Affairs, General Counsel and Secretary for Cornerstone Therapeutics Inc., a public specialty pharmaceutical company. From August 2004 to October 2008, Mr. Townsend served as Senior Vice President, General Counsel and Secretary for Critical Therapeutics, a public biopharmaceutical company. From August 2000 to August 2004, he was a junior partner in the corporate department at Hale and Dorr LLP, now Wilmer Cutler Pickering Hale and Dorr LLP. Prior to joining Hale and Dorr LLP, Mr. Townsend served as a corporate lawyer at Goodwin Procter LLP in Boston, MA and Kilpatrick Stockton LLP in North Carolina. Mr. Townsend received his A.B. from Bowdoin College with a double-major in Economics and Government and Legal Studies and his J.D. from The University of Virginia School of Law.

Edward Jordan

Mr. Edward Jordan is the Senior Vice President - Sales and Marketing of the Company. Mr. Jordan brings to AMAG more than 20 years of experience in U.S. and international pharmaceutical sales and marketing operations. Prior to joining AMAG, Mr. Jordan served as head of sales, marketing, and operations of the women's health division at Teva Pharmaceuticals. In this role he led sales, marketing, training, and sales analytics for their branded pharmaceuticals, over-the-counter products and a medical device. Mr. Jordan began his career at Schering-Plough/Merck where he held various leadership roles of increasing responsibility from 1992 to 2010. During that time, he successfully implemented buy/bill and reimbursement strategies, streamlined sales processes, and led high-caliber sales teams in meeting/exceeding aggressive sales revenue objectives. While at Teva Pharmaceuticals from 2010 to 2014, Mr. Jordan directed a commercial team of 250 people, developing novel market strategies and tactics to address a dynamic healthcare market. Mr. Jordan holds a Bachelor of Science degree in both Finance and Insurance from The University of Rhode Island and a Master of Business Administration from Southern New Hampshire University.

Steven Caffe

Dr. Steven Caffe, M.D., is Senior Vice President, Chief Development and Regulatory Officer of AMAG Pharmaceuticals, Inc. He brings 20 years of experience in global biopharmaceuticals development and regulatory approvals to AMAG. He joins AMAG from MedImmune, AstraZeneca's global biologics research and development arm, where he most recently served as senior vice president of global regulatory affairs and patient safety. Dr. Caffé has broad-based industry experience across several therapeutic areas, and in the development of biopharmaceuticals and medical devices. Early in his career, Dr. Caffé served as a medical director for Parke-Davis, before its acquisition by Pfizer, and has since had roles of increasing responsibility at pharmaceutical companies. Through his experience at Merck & Co., Sanofi, Baxter and most recently MedImmune, Dr. Caffé has assembled and led high-performing teams through many development and regulatory programs, achieving key new product approvals and extending the life cycle of several commercial products. Dr. Caffé received his medical degree from the Faculté de Médecine Saint-Antoine, Université Pierre et Marie Curie (Paris 6), completed his internship and residency, and practiced medicine at the academic hospitals of the Assistance Publique de Paris with a focus on emergency and intensive care.

Melissa Klug

Ms. Melissa Bradford Klug is Senior Vice President - Business Development and Strategy of the Company. For more than 15 years, Ms. Klug has held a variety of senior strategic planning and business development positions in the life sciences industry. As vice president of corporate development at Mallinckrodt Pharmaceuticals, she executed multiple business development transactions and established key financial metrics to support investments or acquisitions of new technologies, assets and companies that aligned with the company's strategic objectives, including the acquisition of CNS Therapeutics and two Phase III assets that formed the foundation for a pain franchise, generating more than $250 million in revenue annually. Ms. Klug also played leadership roles in business development at Baxter International and Eli Lilly and Company. Ms. Klug holds a bachelor's of science in chemistry from Maryville University in St. Louis, Missouri and a master's of business administration from DePaul University in Chicago, Illinois.

Robert Blood

Mr. Robert Blood, Esq. is Chief Compliance Officer, Vice President - Legal Affairs of the Company. Since 2008, Mr. Blood served in various roles of increasing responsibility at EMD Serono, Inc., including most recently as associate general counsel since 2013. In this role, he represented several commercial operation departments and was responsible for contract drafting and negotiations, commercial strategy development and compliance with the laws and regulations of key government agencies. As senior counsel in 2011, he was the lead attorney for EMD Serono's oncology and HIV franchises, which included oversight of several investigational and marketed products. Prior to joining EMD Serono, Mr. Blood held legal positions at the law firm of Goodwin Procter LLP and Montgomery, McCracken, Walker & Rhoads, LLP. Mr. Blood received his J.D. from Northeastern University School of Law and has a bachelor's of science from Georgetown University, School of Foreign Service.

Judith Johnson

Judith Johnson, M.D., has been appointed as Vice President - Pharmacovigilance & Pharmacoepidemiology of AMAG Pharmaceuticals, Inc. Dr. Johnson will have responsibility for all pharmacovigilance functions at AMAG, including product safety surveillance, aggregate safety reporting, pharmacoepidemiology and risk management. She will also oversee the company's compliance with U.S. Food and Drug Administration (FDA) and regulatory requirements for Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse. Over the past ten years, Dr. Johnson has held leadership roles in pharmacovigilance and drug safety at such biopharmaceutical companies as EMD Serono, Inc., AMAG, Genzyme and Parexel. Dr. Johnson received her bachelor's degree from Mount Holyoke College and her medical degree from the University of Pennsylvania School of Medicine. She completed her Ophthalmology, Anesthesia, and General Surgery Residency at George Washington University Medical Center and was a practicing ophthalmologist from 1985 until 2002.

John Fallon

Dr. John Fallon, M.D., has been appointed as Director of AMAG Pharmaceuticals, Inc., effective September 5, 2014. Dr. Fallon brings to the AMAG board broad-based payer, managed care and physician group practice management experience, as well as expertise obtained through his distinguished 25-year career in a variety of physician hospital organizations, integrated delivery systems and academic medical centers. During his tenure at BCBSMA, Dr. Fallon has been responsible for ensuring the highest standards of medical care for the health plan's nearly 3 million members. He is also responsible for helping to expand health care strategies around quality, effectiveness and efficiency.

Lesley Cooper

Dr. Lesley Russell Cooper, MB.Ch.B., MRCP, is an Independent Director of AMAG Pharmaceuticals Inc. She was Senior Vice President and Head of Research and Development for Global Branded Products at Teva Pharmaceuticals, Inc., or Teva, a public pharmaceutical company from October 2011 to June 2012. Dr. Russell was appointed to this role upon Teva's acquisition of Cephalon Inc., or Cephalon, a public pharmaceutical company, where she served as Executive Vice President and Chief Medical Officer from September 2006 to October 2011. She joined Cephalon in 2000 as Vice President, Worldwide Clinical Research. Prior to Cephalon, Dr. Russell served as Vice President, Clinical Research at US Bioscience Inc., a pharmaceutical company, and held positions of increasing responsibility within US Bioscience Inc. from 1996 to 1999. From 1995 to 1996, she was a clinical research physician at Eli Lilly U.K. and a Medical Director at Amgen U.K. from 1992 to 1995. Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MB.Ch.B. from the University of Edinburgh, Scotland and is a member of the Royal College of Physicians, United Kingdom. Dr. Russell is registered with the General Medical Council, United Kingdom. She currently serves on the Board of Directors of Endoycte, Inc., a biopharmaceutical company, where she has been a director since January 2013.

Barbara Deptula

Ms. Barbara H. Deptula has been appointed as Independent Director of AMAG Pharmaceuticals, Inc., effective September 6, 2013. Ms. Deptula served as Executive Vice President of Business Development and Chief Corporate Development Officer of Shire Limited (also known as Shire Pharmaceuticals Group Plc), or Shire, from September 2004 until June 2012. Prior to joining Shire, Ms. Deptula was President of the Biotechnology Division of SICOR Inc. and Senior Vice President for Commercial and Product Development at Coley Pharmaceutical Group. She also held senior management positions focused on marketing, product development, licensing and business development at US Bioscience, Schering Plough, American Cyanamid, and Genetics Institute. She served as an independent director of Combinatorx, Inc. from December 2005 until December 2009. Ms. Deptula received her master’s degree in business administration from the University of Chicago and a bachelor’s of science degree from the University of Connecticut’s School of Pharmacy.

Robert Perez

Mr. Robert J. Perez is Independent Director of AMAG Pharmaceuticals Inc. He is currently President and Chief Operating Officer of Cubist Pharmaceuticals, Inc., or Cubist, a public pharmaceutical company. Mr. Perez joined Cubist in March 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection) and served as Executive Vice President and Chief Operating Officer from August 2007 to July 2012. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS business unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within the commercial organization. From 1987 to 1995 Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. He also served as a member of the Board of Directors of Epix Pharmaceuticals, Inc., a public biopharmaceutical company, from 2006 to 2009. Mr. Perez has been a member of the Board of Trustees of the Dana-Farber Cancer Institute, Inc. since January 2013 and the Board of Advisors of the Citizen School of Massachusetts since 2010. Mr. Perez received a B.S. from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.

Davey Scoon

Mr. Davey S. Scoon, CPA, is Independent Director of AMAG Pharmaceuticals Inc. Mr. Scoon serves as Chairman of the Board of Directors of Tufts Health Plan, where he has been a director since 1981. He has been a member of the Board of Directors of Orthofix International, N.V., a medical device company, since June 2011 and a member of the Board of Directors of Biodel Inc., a public specialty biopharmaceutical company, since April 2012. Mr. Scoon also serves as Chairman of the Board of Trustees of Allianz Funds, a registered investment company consisting of 22 mutual funds, where he has been a director since January 2006. He was the Chairman of the Audit Committee of Cardiokine, Inc., a pharmaceutical company, where he was a director from 2005 to 2011. Mr. Scoon has been an Adjunct Assistant Professor at Tufts University School of Medicine since 2005 and a lecturer in accounting at the University of Wisconsin since 2011. He also previously served as the Chairman of the Audit Committee of NitroMed, Inc., a public pharmaceutical company, from 2003 to 2009, and a member of the Board of Directors of Inotek Pharmaceuticals Corporation, a pharmaceutical company, from 2006 to 2009. From 2003 to 2005, Mr. Scoon was Chief Administrative and Financial Officer of Tom's of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School.

James Sulat

Mr. James R. Sulat is Independent Director of the Company. From October 2009 to June 2013, Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., a public biopharmaceutical company, and as a member of Maxygen’s Board of Directors from October 2003 to June 2013. Since June 2008, Mr. Sulat has served as a member of the Board of Directors and as a member of the Audit Committee for Momenta Pharmaceuticals, Inc., a public biotechnology company (“Momenta”). Since December 2008, Mr. Sulat has also served as the Chairman of Momenta’s Board. From May 2005 to January 2009, Mr. Sulat served in several roles for Memory Pharmaceuticals Corp., a public biopharmaceutical company (“Memory”). He served as Memory’s President and Chief Executive Officer from May 2005 until February 2008, Chief Financial Officer from February 2008 to November 2008, and as a member of Memory’s Board of Directors from May 2005 to January 2009. Since January 2005, Mr. Sulat has served on the Supervisory Board of Intercell AG or its successor company, Valneva SE, both public European biotechnology companies. Mr. Sulat currently serves as Vice Chairman of Valneva’s Supervisory Board and as Chairman of its Audit Committee. Mr. Sulat received his B.S. in Administrative Sciences from Yale University. He received his M.B.A. and his M.S. in Health Services Administration from Stanford University.

Katie Payne

Basic Compensation

Search Stocks